ODI Pharma AB (publ) Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest, by Johan Edewaard, was filed 15 Jan 2026.
ODI Pharma AB (publ): what insiders have been doing
ODI Pharma AB (publ) is a Health Care company. Its directors and officers file their transactions with Finansinspektionen. Over the twelve months to 30 October 2026, 2 filings were filed, from 1 insider.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €4,465, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 chief executive. At €3,502, the purchase published on 15 January 2026 by Johan Edewaard is the largest of the period (0.088% of market cap).
With 2 filings in twelve months, the company is quieter than the median of 9 filings across the 1,035 companies we follow on the same exchange. Looking back to 2020, when coverage begins, insiders filed 4 purchases and 2 sales.
The clock since the last published purchase (15 January 2026) now reads 297 days.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +2.2%Entry SEK 3.70 · Close at T+90 SEK 3.78
- -39.4%Entry SEK 9.76 · Close at T+365 SEK 5.91
- -39.4%Entry SEK 9.76 · Close at T+365 SEK 5.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
- 3,471 shares@ SEK 3.0021.6% of flowAktieISIN SE0013409760FI:csv-641903acc499683e0fdfCanonical exit: 5 Apr 2026 (T+90)
- 10,000 shares@ SEK 3.760.088% mcap100.0% of flowAktieISIN SE0013409760FI:A003V318-1Canonical exit: 8 Apr 2026 (T+90)
- 142,857 shares@ SEK 3.2211.3% of flowAktieISIN SE0013409760FI:csv-de5b075e4a838421a4cd
- 200,000 shares@ SEK 3.5017.5% of flowAktieISIN SE0013409760FI:csv-e918e5d283a200b6b99e
- 2,300,000 shares@ SEK 3.5073.3% of flowAktieISIN SE0013409760FI:csv-c81f11c00a854c125d03
- 128,532 shares@ SEK 12.006556.6% of flowAktieISIN SE0013409760FI:csv-de893a484fb05a7fae5b
- 122,634 shares@ SEK 12.011655.5% of flowAktieISIN SE0013409760FI:csv-6e81f0295c1a885305d9
- 128,532 shares@ SEK 9.2043.4% of flowAktieISIN SE0013409760FI:csv-69904987c1dc88c6f8b1Canonical exit: 15 Apr 2020 (T+90)
- 128,532 shares@ SEK 9.2044.5% of flowAktieISIN SE0013409760FI:csv-a32a33964e7179d88ea2Canonical exit: 15 Apr 2020 (T+90)
9 of 9 declarations
About ODI Pharma AB (publ)
ODI Pharma AB (publ) is a Swedish pharmaceutical company listed on the Stockholm Stock Exchange. It focuses on developing innovative treatments in the healthcare sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
